Document Detail


Novel regulators and drug targets of cardiac hypertrophy.
MedLine Citation:
PMID:  20823714     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiac hypertrophy is classically considered as an adaptive and compensatory response enabling cardiomyocytes to increase their work output and thus cardiac function. Biomechanical stress and neurohumoral activation are the most important triggers of pathological hypertrophy and the transition of cardiac hypertrophy to heart failure. Several novel regulators and putative drug targets of cardiac hypertrophy have been found by using gene-modified and acquired models of cardiac hypertrophy. Recent studies have also revealed distinct patterns of cardiac substrate utilization in cardiac hypertrophy and heart failure. The use of novel systems biology techniques such as metabolomics may therefore in future provide insights into the metabolic processes and cardiovascular biology related to cardiac hypertrophy and also extend the ability to discover circulating biomarkers for cardiovascular diseases. The present review discusses current knowledge on molecular mechanisms of cardiac hypertrophy, with special emphasis on novel regulators and putative drug targets of cardiac hypertrophy such as the tissue renin-angiotensin-aldosterone system, calcineurin/nuclear factor of activated T cells pathway, phosphatidylinositol 3-kinase/growth promoting protein kinase B, mammalian target of rapamycin, histone deacetylases, AMPkinases, microRNAs and angiogenetic factors.
Authors:
Piet Finckenberg; Eero Mervaala
Related Documents :
1338564 - Sympathetic modulation of the cardiac myocyte phenotype: studies with a cell-culture mo...
6446744 - Turnover rates and synthesis of cardiac structural proteins in normal and hypertrophied...
10553914 - Biological reactions in the heart: what should we do in 'cardiology'?
8705764 - Coronary haemodynamics in left ventricular hypertrophy.
11583884 - Increased mortality after coronary artery bypass graft surgery is associated with incre...
19328044 - The extent of the specialized atrioventricular ring tissues.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of hypertension     Volume:  28 Suppl 1     ISSN:  1473-5598     ISO Abbreviation:  J. Hypertens.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-08     Completed Date:  2011-01-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  S33-8     Citation Subset:  IM    
Affiliation:
Institute of Biomedicine, University of Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
AMP-Activated Protein Kinases / metabolism
Angiogenesis Inducing Agents / metabolism
Calcineurin / metabolism
Cardiomegaly / drug therapy*,  metabolism
Histone Deacetylases / metabolism
Humans
MicroRNAs / metabolism
Renin-Angiotensin System / drug effects*
TOR Serine-Threonine Kinases / metabolism
Chemical
Reg. No./Substance:
0/Angiogenesis Inducing Agents; 0/MicroRNAs; EC 2.7.1.1/TOR Serine-Threonine Kinases; EC 2.7.11.1/AMP-Activated Protein Kinases; EC 3.1.3.16/Calcineurin; EC 3.5.1.98/Histone Deacetylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies.
Next Document:  The role of nuclear factor kappa B and nitric oxide interaction in heart remodelling.